<DOC>
	<DOC>NCT00262717</DOC>
	<brief_summary>To compare two commercially available platforms for assessment of HIV drug resistance to determine which provides superior virological results. We hypothesise that one test will be significantly superior to the other.</brief_summary>
	<brief_title>Can Resistance Enhance Selection of Treatment? (CREST)</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>HIV infected patients taking combination antiretroviral therapy, with plasma HIV RNA&gt; 2000copies/mL, who were willing to change ARVs and who provided informed consent. Patients who were ARV na√Øve, who were experiencing an acute illness or judged to be unable to comply with the protocol requirements.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>HIV drug resistance testing</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>